Tepmetko Tepotinib MET Exon 14 Skipping NSCLC Review 2026
Author: Critical Kare PharmaPrecision Oncology Desk
On October 23, 2026, pulmonary oncology panels reviewed Tepmetko® (Tepotinib 225 mg film-coated tablets) by EMD Serono / Merck KGaA as the first once-daily oral MET inhibitor for advanced NSCLC harboring MET exon 14 skipping alterations.
Engineered with exceptional biochemical selectivity for the ATP-binding pocket of MET kinase, Tepmetko offers once-daily oral administration and durable therapeutic responses detected via liquid biopsy or tissue next-generation sequencing.
Through Critical Kare Pharma, certified genuine packs of Tepmetko Tepotinib 225mg Tablets are supplied directly to oncology centers and named patients globally.
The VISION Trial Clinical Milestones
- Robust Response Profile: Confirmed 56.8% objective response rate in treatment-naive patients and 45.0% in previously treated patients.
- Convenient Once-Daily Dosing: Two 225 mg tablets taken together (450 mg total) orally once daily with food.
- Managing Peripheral Edema: Monitor for fluid retention; manageable with dose interruptions and supportive compression or diuretic therapy.
Global Named-Patient Access
Coordinated under US FDA PIP, UK Named-Patient Import, and Latin American health permits with full batch traceability.
